Sex Differences in Cardiac Transplantation

Chung, Alice; Hartman, Heidi; DeFilippis, Ersilia M.

doi:10.1007/s11883-023-01169-0

Cited by 4 publications

(2 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results were found by Chung et al (2023). In view of this, we consider it a limitation of the study 48 .…”

Section: Discussionmentioning

confidence: 99%

Aortic pulse wave analysis and functional capacity of heart transplantation candidates: a pilot study

Alcici-Moreira,

Vitarelli,

Velloso

et al. 2024

Sci Rep

View full text Add to dashboard Cite

We compared cardiovascular parameters obtained with the Mobil-O-Graph and functional capacity assessed by the Duke Activity Status Index (DASI) before and after Heart Transplantation (HT) and also compared the cardiovascular parameters and the functional capacity of candidates for HT with a control group. Peripheral and central vascular pressures increased after surgery. Similar results were observed in cardiac output and pulse wave velocity. The significant increase in left ventricular ejection fraction (LVEF) postoperatively was not followed by an increase in the functional capacity. 24 candidates for HT and 24 controls were also compared. Functional capacity was significantly lower in the HT candidates compared to controls. Stroke volume, systolic, diastolic, and pulse pressure measured peripherally and centrally were lower in the HT candidates when compared to controls. Despite the significant increase in peripheral and central blood pressures after surgery, the patients were normotensive. The 143.85% increase in LVEF in the postoperative period was not able to positively affect functional capacity. Furthermore, the lower values of LVEF, systolic volume, central and peripheral arterial pressures in the candidates for HT are consistent with the characteristics signs of advanced heart failure, negatively impacting functional capacity, as observed by the lower DASI score.

show abstract

“…Similar results were found by Chung et al (2023). In view of this, we consider it a limitation of the study 48 .…”

Section: Discussionmentioning

confidence: 99%

Aortic pulse wave analysis and functional capacity of heart transplantation candidates: a pilot study

Alcici-Moreira,

Vitarelli,

Velloso

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…There are several predisposing factors responsible for this particular complication reflected in the RADIAL score, and they are right atrial pressure > 20 mmHg, donor age > 30 years, recipient age > 60 years, graft ischemia time > 4 h. Others are pre-operative LVAD use, female gender [85,86], obesity [87], and diabetes [88]. When donor risk factors are categorized, they are brain death, use of intravenous inotropes, age, and dysfunction of another donor graft.…”

Section: Primary Graft Failurementioning

confidence: 99%

Heart Transplantation

Chrysakis,

Magouliotis,

Spiliopoulos

et al. 2024

JCM

View full text Add to dashboard Cite

Heart transplantation (HTx) remains the last therapeutic resort for patients with advanced heart failure. The present work is a clinically focused review discussing current issues in heart transplantation. Several factors have been associated with the outcome of HTx, such as ABO and HLA compatibility, graft size, ischemic time, age, infections, and the cause of death, as well as imaging and laboratory tests. In 2018, UNOS changed the organ allocation policy for HTx. The aim of this change was to prioritize patients with a more severe clinical condition resulting in a reduction in mortality of people on the waiting list. Advanced heart failure and resistant angina are among the main indications of HTx, whereas active infection, peripheral vascular disease, malignancies, and increased body mass index (BMI) are important contraindications. The main complications of HTx include graft rejection, graft angiopathy, primary graft failure, infection, neoplasms, and retransplantation. Recent advances in the field of HTx include the first two porcine-to-human xenotransplantations, the inclusion of hepatitis C donors, donation after circulatory death, novel monitoring for acute cellular rejection and antibody-mediated rejection, and advances in donor heart preservation and transportation. Lastly, novel immunosuppression therapies such as daratumumab, belatacept, IL 6 directed therapy, and IgG endopeptidase have shown promising results.

show abstract